🇺🇸 FDA
Company

Apellis

Apellis Pharmaceuticals

APLS pharma USA

Quick answer

Apellis is a pharma company (APLS) headquartered in WALTHAM, MA, USA with 20 tracked pipeline programs.

Pipeline (20)

project

APL-2

Geographic Atrophy

Phase 3 · small_molecule · completed

2 trials project

APL-2

Paroxysmal Nocturnal Hemoglobinuria

Phase 3 · small_molecule · completed

1 trials project

APL-2, Pegcetacoplan

Geographic Atrophy Secondary to Age-related Macular Degeneration

Phase 3 · small_molecule · completed

1 trials project

APL2

FSGS

Phase 3 · small_molecule · active

1 trials project

PEGCETACOPLAN (APL-2)

Geographic Atrophy Secondary to Age-related Macular Degeneration

Phase 3 · small_molecule · completed

1 trials project

Pegcetacoplan

C3G

Phase 3 · small_molecule · active

3 trials project

Pegcetacoplan

PNH

Phase 3 · small_molecule · active

2 trials project

Pegcetacoplan

Paroxysmal Nocturnal Hemoglobinuria

Phase 3 · small_molecule · completed

2 trials project

Pegcetacoplan

Delayed Graft Function

Phase 3 · small_molecule · active

1 trials project

APL-2

Warm Autoimmune Hemolytic Anemia

Phase 2 · small_molecule · completed

1 trials project

APL-2

IgA Nephropathy

Phase 2 · small_molecule · completed

1 trials project

APL-3007, pegcetacoplan (APL-2)

Geographic Atrophy Secondary to Age-related Macular Degeneration

Phase 2 · small_molecule · active

1 trials project

APL-9

COVID

Phase 2 · small_molecule · completed

1 trials project

Pegcetacoplan

Transplant-Associated Thrombotic Microangiopathy

Phase 2 · small_molecule · completed

1 trials project

Pegcetacoplan

Geographic Atrophy

Phase 2 · small_molecule · completed

1 trials project

Pegcetacoplan

Neovascular Age-related Macular Degeneration

Phase 2 · small_molecule · terminated

2 trials project

Pegcetacoplan

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Phase 2 · small_molecule · active

2 trials project

Pegcetacoplan (APL-2)

Amyotrophic Lateral Sclerosis

Phase 2 · small_molecule · terminated

1 trials project

PEGCETACOPLAN (APL-2)

Geographic Atrophy

Phase 1 · small_molecule · completed

1 trials project

Virtual Reality (VR) Contrast Function Test

Age-Related Macular Degeneration

Unknown · other · active

1 trials

Drugs (1)

drug

pegcetacoplan

SYFOVRE

Patents (8)

patent

US 12290566

Dosing regimens and related compositions and methods

Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12251395

RNAS for complement inhibition

Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11903994

Dosing regimens

Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11844841

Dosing regimens and related compositions and methods

Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11712460

Methods of treating chronic disorders with complement inhibitors

Expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11661441

Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof

Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11510939

RNAs for complement inhibition

Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11407789

Cell-penetrating compstatin analogs and uses thereof

Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)